Cargando…
Commercializing the stem cell sciences /
Promising new developments in biomedical technology such as stem cell science are widely endorsed by governments keen to reduce spiralling healthcare costs, clinicians focused on patient care, and patients demanding revolutionary new treatments. Commercializing the stem cell sciences offers a compar...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Oxford :
Woodhead Publishing,
2012.
|
| Colección: | Woodhead Publishing series in biomedicine ;
no. 12. |
| Temas: | |
| Acceso en línea: | Texto completo |
Tabla de Contenidos:
- Cover; Commercializing thestem cell sciences; Copyright; Contents; Acknowledgements; List of abbreviations; About the author; 1 Introduction: stem cell science, biotechnology and the problem of commercialization; 1.1 Modelling the most successful biotech business in the world; 1.2 Emerging stem cell therapies and the commercialization of biotechnology; 1.3 Some prospective possibilities for the stem cell industries; 1.4 The limits of commercialization in the stem cell sciences; 1.5 What are the most lucrative commercial models to adopt?; References.
- 2 Stem cell treatments in a global marketplace2.1 Patients drive the market; 2.2 Healthcare providers and the consumption of stem cell technologies; 2.3 Stem cell tourism: is it a fraud or a worthwhile endeavour?; 2.4 The lucrative potential of animal applications of stem cell products and techniques; 2.5 What is the potential for market share?; References; 3 The role of innovation systems in the commercialization of biotechnology; 3.1 The international context of stem cell science; 3.2 The key components of national innovation systems.
- 3.3 The intersection between commercialization and innovation3.4 Globalization and innovation systems?; References; 4 Low-risk, low-value: adult stem cells; 4.1 A brief history of adult stem cell technologies; 4.2 Adult stem cell science in the twenty-first century; 4.3 So where are the commercial opportunities?; References; 5 High-risk, high-value: embryonic stem cells; 5.1 The global debate; 5.2 Current clinical trials; 5.3 The future of hESC research?; References; 6 Low-risk, low-value: iPS cells; 6.1 iPSCs and the autologous solution; 6.2 Imagined scenarios; 6.3 The iPS cell industry?